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Repetitive stent fRACtuRes with diffuse 
CoRonARy ARteRy miCRoAneuRysm foRmAtion – 
siRolimus eluting stent hypeRsensitivity? 
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summARy – while drug eluting stents (des) are being more widely used in ever more pati-
ents receiving des each day, some new complications may be emerging. stent fractures and hyper-
sensitivity reactions to stents are among recognized complications that can lead to therapeutic dead 
end from the interventional cardiologist’s point of view. we present a case in which we reached 
therapeutic dead end with a sirolimus eluting stent, i.e. repetitive stent fractures with diffuse micro-
aneurysms along the implanted des, possibly due to hypersensitivity reaction to parts of the stent.
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Introduction 
drug eluting stents (des) have been ever more 
widely used since their first introduction in 20001,2. 
After first studies, a sirolimus eluting stent (ses; 
Cypher) was approved in europe in 2002 and by the 
food and drug Administration (fdA) in the usA in 
2003. until today, over 3 000 000 sirolimus eluting 
stents have been implanted in the world3. 
since then, some negative features regarding safe-
ty of the first generation dess have been reported, 
with late and very late stent thrombosis certainly as 
most extensively explored, and on the other hand, the 
possible hypersensitivity to ses as underestimated 
one. Although there are case reports in the literature 
as well as reports from the fdA and the Research on 
Adverse drug events and Reports (RAdAR), the real 
incidence, prevalence and consequences of hypersen-
sitivity to des are not known, as well as the possible 
role in some cases of stent thrombosis4,5. we describe 
a patient who developed repetitive stent fractures, in-
stent restenosis and diffuse coronary artery wall dila-
tation with the risk of stent thrombosis, all possibly 
caused by des hypersensitivity. 
Case Report 
we present a 62-year-old female patient with a his-
tory of hyperlipidemia and coronary artery disease, who 
underwent several coronary angiographies with inter-
ventions on RCA and lAd. The patient was first treated 
with 2 sess in lAd, and then 6 months later with 2 
bare metal stents in RCA. one year after the first pro-
cedure, coronary angiography performed due to positive 
eCg stress test showed focal fracture of distal sirolimus 
stent in the lAd with aneurysm formation, which was 
successfully treated with graft stent implantation6.
during routine follow-up at 3 and 6 months af-
ter graft stent implantation, the patient was symptom 
free and had negative eCg stress. one year after the 
implantation, the patient was admitted because of a 
positive eCg stress test, although she still remained 
symptom free.
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upon admission and routine preparation, the pa-
tient underwent coronary angiography, which showed 
RCA with no in-stent restenosis, while lAd showed 
50% in-stent restenosis in the graft stent implanted 
one year earlier, new stent fracture proximally (ses 
implanted two years before), and diffuse microaneu-
rysmatic changes with delayed contrast filling along 
previously implanted proximal ses. Angiography 
also revealed slow flow (timi ii-iii) in lAd distally 
to implanted stents (figs. 1-4).
Because the patient underwent two interven-
tions on the lAd with two ses implantation and 
graft stent implantation in previous fracture, further 
percutaneous intervention on the lAd was not rea-
sonable. The only remaining therapeutic option was 
coronary artery bypass surgery. Although coronary 
bypass would have solved ischemia in the lAd per-
Fig. 1. RAO cranial view showing 50% in-stent resteno-
sis in graft stent implanted in LAD and arterial dilata-
tion with microaneurysms along the previously implanted 
sirolimus eluting stent.
Fig. 2. RAO cranial view enlarged.
Fig. 3. LAO caudal view showing arterial dilatation 
with microaneurysms of the proximal LAD.
Fig. 4. RAO cranial view of the fractured stent. 
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fusion area, there would still remain the risk of in-
stent thrombosis with the loss of a substantial area 
of viable myocardium. we had reached a therapeutic 
dead end.
The patient was informed of the finding and on the 
possible need of cardiac bypass surgery and all peri- 
and postoperative risks. since the patient was asymp-
tomatic, she decided to postpone the surgery for some 
time.
she was discharged from the hospital several days 
later with dual anti-aggregation therapy (dAt) with 
aspirin and double dose clopidogrel, high dose statin, 
beta blocker, long acting nitrate and trimetazidine, with 
a recommendation for regular, frequent follow-ups.
Discussion 
The key message of this report is to point out that 
with implantation of des, a therapeutic cul-de-sac 
could be reached and could potentially lead to the 
worst possible outcome. in a previous report, we 
presented a patient with stent fracture and coronary 
artery aneurysm and described the incidence accord-
ing to the literature, the possible mechanisms and 
therapeutic options for stent fractures6. we have now 
found that the same patient has a new stent fracture 
in previously implanted ses with arterial dilatation 
and multiple aneurysmatic changes of the lAd along 
the whole length of previously implanted ses. The 
first stent fracture occurred in distal ses, whereas the 
new fracture is in the proximal one. of importance 
is that proximal stent was not overinflated with non-
compliant balloon, nor was it implanted in the area of 
lAd ‘’bridging’’, both of these regarded as risk fac-
tors for first stent fracture.
while stent fracture could be explained by me-
chanical factors (longer and overlapping stents, 
Cypher stent implantation, excessive high pressure 
postdilatation, right coronary artery intervention, 
myocardial bridging and procedure in tortuous le-
sions)7-10, the etiology of repetitive stent fractures in 
the same patient with diffuse arterial dilatation and 
microaneurysmatic changes is more complex.
Because changes seen on the last angiogram are 
diffuse along the whole length of proximal ses and 
could not be found along other parts of lAd or along 
bare metal stents in the RCA, one possible explana-
tion is reaction to components of ses (Cypher, Cordis 
Johnson & Johnson). 
since our patient has normal leukocyte count with 
normal eosinophils, we can only assume a hypersen-
sitivity reaction to her des based on clinical and an-
giographic findings, bearing in mind previous reports 
and findings10.
in this particular case, there is evidence for three 
stent-driven complications: a stent fracture that is a 
mechanical event, aneurysmal arterial dilatation that 
is probably caused by inflammatory response and con-
sequential arterial wall weakening, and in-stent rest-
enosis, which is not frequent event with des. After 
detailed case analysis and literature review, several is-
sues remain unsolved: first, which component of the 
stent is the causative trigger; second, which event was 
initial; and third and most important, what is the op-
timal treatment approach for our patient.
The suspected hypersensitivity reaction could be to 
the metallic stent, polymer or sirolimus. Cypher stents 
have 0.0055’’ thick 316l stainless steel struts and are 
coated with a layer of a poly-n-butyl methacrylate and 
polyethylene-vinyl acetate copolymer containing 140 
µg sirolimus (wyeth-Ayers)11. 
The first possibility is a hypersensitivity reaction 
to nickel or molybdenum from the stainless steel of 
the metal struts, but previous studies have not shown 
hypereosinophilic reactions in human autopsies over 
400 Bms10 . Also, the patient has no changes along 
Bms implanted in RCA.
sirolimus is the other possible cause of hypersensi-
tivity reaction, although it usually reduces eosinophilic 
infiltration and is associated with low levels of hyper-
sensitivity4. Also, since 80% of sirolimus is released in 
the first 30 days and the drug is undetectable in arte-
rial wall after 60-90 days according to animal stud-
ies11, a reaction to sirolimus in our patient is highly 
unlikely (the patient underwent coronary angiography 
6 and 12 months after the first procedure, and diffuse 
arterial changes were not detected).
on the other hand, late hypersensitivity to des 
with possible reaction to polymer has been described10, 
with arterial wall dilatation as a positive arterial re-
modeling provoked by inflammatory reaction. Also, a 
review of cases by the RAdAR from 2006 has identi-
fied 262 cases with hypersensitivity symptoms in pa-
tients with des4. Among these cases, 17 were identi-
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fied as certainly or probably caused by des, and 14 of 
these by Cypher. four patients had in-stent thrombo-
sis and died, and pathology reports are the strongest 
evidence of des causing hypersensitivity reactions. 
pathology report from the case reported by virmani 
et al. showed aneurysmally dilated artery with exten-
sive inflammatory infiltrate of the intima, media and 
adventitia with medial destruction. infiltrates con-
sisted of lymphocytes, plasma cells, macrophages and 
eosinophils10.
Regarding therapeutic options, as we said be-
fore, we decided to discharge the patient with dAt, 
postponing the decision on revascularization. Al-
though the patient is asymptomatic, we have strong 
evidence of lAd territory ischemia and indication 
for ischemia-driven target vessel revascularization. 
Additional percutaneous revascularization is not an 
option because we do not have evidence for the safety 
of additional des with a different drug and polymer, 
and we assumed that it could be deleterious for the 
patient. There is an option for treatment of in-stent 
graft restenosis with drug eluting balloon, but this is 
probably not culprit lesion for ischemia. on the other 
hand, coronary artery bypass graft with a mammary 
artery offers the optimal solution for ischemia, but we 
cannot predict the development of further aneurysmal 
dilatation with the possibility of in-stent thrombosis 
and/or aneurysm rupture. 
Although some reports describe regression or at-
tenuation of hypersensitivity symptoms after therapy 
with corticosteroids, none of them included patients 
with focal reaction and arterial wall dilatation4. so, 
the option of corticosteroid administration remains 
open because it could be life-saving, but with several 
reasons for caution; we could not prove an inflamma-
tory or hypersensitivity reaction by any laboratory test 
or imaging technique and corticosteroids could accel-
erate pre-existing atherosclerotic disease. This is why, 
at this moment, we have decided not to start the pa-
tient on steroids, but the wisest solution could be to 
schedule the patient for bypass surgery, with intraop-
erative biopsy, and in case of positive hypersensitivity 
to start corticosteroid administration with the inten-
tion to stop dilatation progression. 
This case shows the need of close and careful fol-
low-up of patients treated with des, thinking of pos-
sible complications and diagnosing them on time. 
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sažetak
opetovAne fRAKtuRe stentA uZ nAstAnAK difuZnih miKRoAneuRiZAmA KoRonARne 
ARteRiJe – pReosJetlJivost nA stent KoJi iZlučuJe siRolimus?
N. Pavlović, K. Štambuk, I. D. Gabrić, M. Trbušić, T. Krčmar, Š. Manola, H. Pintarić, V. Radeljić, D. Delić-Brkljačić 
i O. Vinter
dok se stentovi koji ispuštaju lijekove sve više primjenjuju kod bolesnika svakodnevno, moguća je pojava novih kom-
plikacija. prijelomi stenta i reakcije preosjetljivosti na stentove neke su od poznatih komplikacija koje mogu dovesti do te-
rapijski bezizlazne situacije sa stajališta intervencijskog kardiologa. prikazuje se upravo takav slučaj sa stentom koji izlučuje 
sirolimus, gdje su nastupili opetovani prijelomi stenta uz difuzne mikroaneurizme duž ugrađenog stenta, moguće zbog 
reakcije preosjetljivosti na dijelove stenta.
Ključne riječi: Koronarni stent, restenoza; Proteza, otkazivanje; Stentovi koji izlučuju lijek; Koronarna aneurizma

